- Home
- PBA vs BIIB Comparison
PBA vs BIIB Comparison
Compare PBA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- BIIB
- Stock Information
- Founded
- PBA 1997
- BIIB 1978
- Country
- PBA Canada
- BIIB United States
- Employees
- PBA N/A
- BIIB N/A
- Industry
- PBA Oil & Gas Production
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PBA Energy
- BIIB Health Care
- Exchange
- PBA Nasdaq
- BIIB Nasdaq
- Market Cap
- PBA 21.6B
- BIIB 18.7B
- IPO Year
- PBA N/A
- BIIB 1991
- Fundamental
- Price
- PBA $39.37
- BIIB $143.68
- Analyst Decision
- PBA
- BIIB Buy
- Analyst Count
- PBA 0
- BIIB 27
- Target Price
- PBA N/A
- BIIB $188.09
- AVG Volume (30 Days)
- PBA 1.5M
- BIIB 1.5M
- Earning Date
- PBA 11-04-2025
- BIIB 10-29-2025
- Dividend Yield
- PBA 5.09%
- BIIB N/A
- EPS Growth
- PBA N/A
- BIIB 31.67
- EPS
- PBA 2.18
- BIIB 10.45
- Revenue
- PBA $5,911,897,112.00
- BIIB $9,997,000,000.00
- Revenue This Year
- PBA $10.93
- BIIB $2.00
- Revenue Next Year
- PBA $7.81
- BIIB N/A
- P/E Ratio
- PBA $18.04
- BIIB $13.76
- Revenue Growth
- PBA 20.59
- BIIB 3.36
- 52 Week Low
- PBA $34.13
- BIIB $110.04
- 52 Week High
- PBA $43.44
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- PBA 67.28
- BIIB 58.49
- Support Level
- PBA $38.32
- BIIB $141.12
- Resistance Level
- PBA $39.33
- BIIB $150.28
- Average True Range (ATR)
- PBA 0.54
- BIIB 4.61
- MACD
- PBA 0.14
- BIIB 0.30
- Stochastic Oscillator
- PBA 99.54
- BIIB 64.82
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.